



News Release

Suven Life Sciences secures Two (2) Product Patents in Australia & New Zealand for Their New Chemical Entities (NCEs)

HYDERABAD, INDIA (October 31st, 2007) – Suven Life Sciences Ltd announces today that two of their New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases were granted patents in Australia (2003-249582 and 2003-249583) and New Zealand (537770 and 537772) and these Patents are valid until 2022.

The granted claims of these patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like **Alzheimer's, Attention deficient hyperactivity, Huntington's, Parkinson and Schizophrenia.**

Suven thus far **has filed 25 product patents** under PCT out of which 10 has entered national phase. These are the first Product Patents granted to Suven from our four years of drug discovery efforts. Suven has already filed its first **Investigational New Drug (IND)** application with DCGI to conduct the clinical Phase-I study on their developmental candidate **SUVN-502.**

We continue to work on G-Protein coupled receptor (GPCR) targets to discover and develop molecules focusing on CNS disorders with unmet medical need and high market potential, says Venkat Jasti, CEO of Suven.

Suven Life Sciences is a Hyderabad based Life Science company, a **Collaborative Research Partner (CRP)** since 2006 in Drug Discovery for global Pharma major and is a pioneer in **Contract Research and Manufacturing Services (CRAMS)** since 1995 and **Drug Discovery and Development Support Services (DDDSS)** since 2005. Suven has been involved in development of path breaking technologies for global pharma companies for more than a decade.

A focused provider of DDDSS for development of New Chemical Entities to life sciences companies, Suven's commitment to protection of intellectual property, maximization of return on R&D investments for collaborative research partners, ability to offer full spectrum of services from discovery to market launch and provide technologies and expertise in different therapeutic areas. Suven has R&D strength of more than 255 professionals with the state of the art infrastructure for Drug Discovery and development activities and the front end project management services from New Jersey, USA. For more information on Suven, please visit our Web site at www.suven.com

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

